ABSTRACT: Statins are cholesterol-lowering drugs that inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a ratelimiting enzyme of the mevalonate pathway. The anti-inflammatory effect of statins has been reported in recent years. The present study investigated therapeutic effects of the local administration of statin in osteoarthritis (OA). We assessed clinically used statins and selected fluvastatin for further experimentation, as it showed potent anabolic and anti-catabolic effects on human OA chondrocytes. To achieve controlled intra-articular administration of statin, we developed an intra-articular injectable statin using poly(lactic-co-glycolic acid) (PLGA) as a drug delivery system (DDS). The release profile of the statin was evaluated in vitro. Finally, therapeutic effects of fluvastatin-loaded PLGA microspheres (FLU-PLGA) were tested in a rabbit OA model. Rabbit knees were divided into four subgroups: group 1-A, PLGA-treated group; group 1-B, PLGA contralateral saline control group; group 2-A, FLU-PLGA-treated group; and group 2-B, FLU-PLGA contralateral saline control group. Histological analysis 5 weeks after intra-articular injection revealed that OARSI scores were lower in group 2-A. No significant differences in OARSI scores were observed between groups 1-A, 1-B, and 2-B. This study indicates that a single intra-articular injection of fluvastatin-loaded PLGA microspheres could be a novel therapeutic approach for treating patients with OA. Keywords: fluvastatin; statin; PLGA microspheres; intra-articular injection; osteoarthritis Osteoarthritis (OA) is a major cause of decreased activity in daily life. It is characterized by the progressive loss of articular cartilage that leads to chronic pain and functional restrictions in affected joints. These changes finally cause loss of productivity and reduced quality of life.
Osteoarthritis (OA) is a major cause of decreased activity in daily life. It is characterized by the progressive loss of articular cartilage that leads to chronic pain and functional restrictions in affected joints. These changes finally cause loss of productivity and reduced quality of life. 1 Most of the cartilage is composed of extracellular matrix (ECM), and the major components of the ECM are collagen type II and aggrecan. 2, 3 In the progression of OA, these ECM components are gradually degraded, and cytokines and matrix-degrading enzymes play a key role in this step. 4 Matrix metalloproteinases (MMPs) are significantly upregulated by proinflammatory cytokines such as IL-1b, which is produced by synoviocytes in the synovial fluid. 5 MMPs can directly destroy various components of the cartilage matrix, such as collagen type II and aggrecan. 6 In this way, MMPs have a major impact on OA cartilage degeneration. Recent research for OA treatment has focused on finding agents that can decrease the expression of catabolic factors in order to slow or halt OA progression. 7 However, there are no currently used pharmacological treatments that prevent the development of OA. 8 Statins are cholesterol-lowering drugs that inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (Fig. 1A) , a rate-limiting enzyme of the mevalonate pathway. 9 This drug has pleiotropic effects, including anti-inflammatory effects. 10 However, it has severe side effects such as rhabdomyolysis when systemically administered in high doses 11 ; therefore, local administration is desirable in order to obtain a beneficial effect in cartilage. A previous study reported that weekly repeated local injections of statin into knee joints of an OA animal model can inhibit disease progression. 12 However, a method for sustaining the release of statin within the knee joint is desired to enhance the therapeutic effect and improve the convenience of statin in clinical use.
In this study, poly (lactic-co-glycolic acid) (PLGA) (Fig. 1B) microspheres were selected as possible statin carriers because of their injectable and biodegradable properties 13, 14 and the sustained-release profile of statin. 15, 16 Based on these characteristics, we examined the potential of statin-loaded PLGA microspheres as protective agents against cartilage degradation in OA, both in vitro and in vivo.
First, the effects of various statins were evaluated in human chondrocytes, and detailed assessment was done using fluvastatin with or without stimulation of IL-1b. Based on this in vitro study, we fabricated fluvastatin-loaded PLGA microspheres (FLU-PLGA) and assessed their function and morphology. Finally, a rabbit model of OA was used to evaluate the in vivo effects of FLU-PLGA. We hypothesized that intra-articular injections of FLU-PLGA would reducecartilage degradation and increase the production of extracellular matrix in an experimental OA model.
METHODS Materials
Gelatin, polyvinyl alcohol, dichloromethane, and PLGA-7510 were purchased from Wako Pure Chemical Industries (Osaka, Japan). Fluvastatin was obtained from Toronto Research Chemicals (North York, Canada). Japanese white rabbits weighing 3.0-3.5 kg with closed epiphyses were purchased from SLC (Shizuoka, Japan).
Fabrication of Fluvastatin-Impregnated PLGA Microspheres Fluvastatin-impregnated PLGA microspheres (FLU-PLGA) were prepared using an in-water drying method as previously reported (Fig. 1C) . 15, 17 Briefly, the inner water phase consisted of 450 mg of fluvastatin in a mixture of 2.5 ml of water and 400 mg of gelatin at approximately 60˚C. The oil phase consisted of 4 g of PLGA dissolved in 20 ml of dichloromethane solution. The oil phase was gradually poured into the inner water phase under vigorous stirring with a magnetic stirrer over 3 min to make a water/oil (w/o) emulsion. The emulsion was then poured into 400 ml of an aqueous 0.25% polyvinyl alcohol solution under vigorous stirring with a magnetic stirrer over 10 min to make a (w/o)/w emulsion. To evaporate the dichloromethane, the (w/o)/w emulsion was gently stirred with a magnetic stirrer for 3 h. The hardened microspheres in the wet state were sized using sieves with apertures of 70 mm, rinsed with water three times, and lyophilized into powders. We also created PLGA microspheres without statin as a control.
Observation and Release Testing of Microspheres
The freeze-dried fluvastatin-loaded microspheres (2 mg) were suspended in 2 ml phosphate-buffered saline (PBS, pH 7.4) in test tubes. Then, the tubes were kept under constant shaking (60 rpm) at 37˚C. For the determination of release kinetics of fluvastatin from microspheres, total PBS (2 ml) was collected after centrifugation. The supernatant was analyzed with a spectrophotometer (EnSight Multimode Plate Reader; PerkinElmer, Waltham, MA) at 240 nm. Blank microspheres were subjected to the same procedure, and the supernatant obtained was used as a blank at the corresponding time points. All release experiments were carried out in triplicate. To examine the morphology of the microspheres, the residues were freezedried and examined using a scanning electron microscope (SEM) (TM3000; Hitachi, Tokyo, Japan).
Cell Isolation and Cultures
Human articular cartilage fragments were collected aseptically from OA patients who had undergone knee joint replacement and had provided informed consent for the use of chondrocytes, as required by the Ethics Committee of Kyushu University Hospital. The cartilage fragments were then digested by 2 mg/ml of collagenase (Collagenase; Wako, Osaka, Japan) in DMEM/F12 (Gibco, Langley, OK). Collagenase digestion was carried out at 37˚C for 12 h with moderate stirring. For routine cultures, chondrocytes were maintained in DMEM/F12 with 10% FBS (Gibco) in a humidified atmosphere containing 5% CO 2 and used for the experiments within passage 2.
Assessment of Various Statins
Chondrocytes were pre-treated for 24 h in culture medium containing 10% FBS with fluvastatin, simvastatin, and rosuvastatin at concentrations of 0 or 10 mM each. Cells were then harvested and processed for RT-PCR. Total RNA was extracted using an RNeasy Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. Complementary DNA was synthesized using PrimeScript RT reagent Kit (Takara Bio, Shiga, Japan), and the resulting cDNA was amplified with PCR using a commercially available kit (SYBR Premix Ex Taq, Takara Bio). All PCR reactions were performed using a LightCycler 2.0 Instrument (Roche, Basel, Switzerland). Expression of two major matrix-composing markers (collagen type II and aggrecan), the key chondrogenic gene Sox9, and the matrix degenerative enzyme MMP13 were examined. GAPDH was used as an internal control in PCR amplification, and the relative normalization ratio of PCR products derived from each target gene was calculated. Cell Viability Assay Chondrocytes were seeded in 96-well plates (5.0 Â 10 3 cells/ well). After incubation with fluvastatin at 0, 1, 10, and 25 mM, the cell viability assay was carried out using a CellTiter-Glo Luminescent Cell Viability Assay kit (Promega, Fitchburg, WI) in accordance with the manufacturer's protocol. Luminescence was measured using a MicroLumatPlus LB96V Microplate Luminometer (EG&G Berthold, Bad Wildbad, Germany). Data from three independent experiments were analyzed.
Real-Time PCR Cells were pre-treated for 18 h in culture medium containing 10% FBS with 0, 1, and 10 mM fluvastatin, and then stimulated with 1 ng/ml of IL-1b for 6 h. A sample cultured in the absence of IL-1b was also evaluated. Cells were then harvested and processed for RT-PCR according to the manufacturer's instructions as described previously. This experiment was repeated in four samples, each from different donors.
Enzyme-Linked Immunosorbent Assay (ELISA)
Cells were pre-treated for 66 h in culture medium containing 10% FBS with 0, 1, and 10 mM fluvastatin, and then stimulated with or without 1 ng/ml of IL-1b for 6 h. To account for transcription and secretion lag time, the total fluvastatin treatment time was 72 h. Culture media were then collected for ELISA. The levels of MMP-13 produced by chondrocytes were measured using MMP13 Human ELISA Kit (Abcam, Cambridge, UK) in accordance with the manufacturer's protocol. This experiment was repeated in three samples, each from different donors.
In Vivo Effects of FLU-PLGA Microspheres on Surgically Induced Osteoarthritis: The Anterior Cruciate Ligament Transection (ACLT) Model
ACLT Model
The animal experiments conducted as a part of this study were approved by the Animal Research and Care Committee of our institution. Female Japanese white rabbits (3.0-3.5 kg) were purchased for this study. After a week acclimation and confirmation of healthy condition, the rabbits were used for the experiment. Following an intramuscular injection of 10% ketamine (30 mg/kg) and 2% xylazine (5.0 mg/kg), anesthesia was maintained using 10% ketamine (10 mg/kg) and 2% xylazine (3.0 mg/kg) delivered via intravenous injection. The knee joint was exposed by medial parapatellar incision. After the joint capsule was opened, the anterior cruciate ligament was transected using surgical scissors. Following irrigation of the operated site with saline, the capsule and skin were sutured separately. The capsule was sutured within a relatively narrow interval to prevent drug leakage. Postoperatively, the rabbits were single housed, and allowed free cage activity, eating, and drinking. Knee joint spaces of rabbits in group 2 were treated with 1 mg/kg FLU-PLGA (containing approximately 0.03 mg of fluvastatin) suspended in 0.2 ml/kg of normal saline. Knee joint spaces of rabbits in group 1 received the same amount of PLGA without fluvastatin. The knee on one side selected at random was injected with PLGA with or without fluvastatin (subgroup A), and the contralateral knee was injected with normal saline as an untreated control (subgroup B) (Fig. 1D) . Every injection was performed 7 days after ACLT. The in vivo dose of fluvastatin was determined by referring to the in vivo minimum effective dose of a previous study. 12 Rabbits were sacrificed 6 weeks after ACLT (Fig. 1E) . Each group had five rabbits.
Classification of Animals

Macroscopic Observation
Each group was evaluated by gross morphological examination. Following sacrifice, gross morphological grading was performed in a blind fashion after applying India ink. The severity of gross morphological changes was graded as 1 (intact surface), 2 (discoloration, minimal surface fibrillation), 3 (overt surface fibrillation), or 4 (full-thickness erosion and/or osteophytes) based on a previous report. 18 The brightness of all images was adjusted simultaneously and identically to improve comprehension. The original images are provided as a supplemental file.
Histology Articular cartilage of all groups was histologically examined. The medial femoral condyles of both knees were fixed in 4% FLUVASTATIN-PLGA MICROSPHERES REDUCE OSTEOARTHRITIS paraformaldehyde for 3 days. After decalcification, the femoral condyles were cut along the sagittal plane and embedded in paraffin. Four-micron sections were stained with safranin-O-fast green. In brief, slides were deparaffinized with xylene and alcohol. After a 5-min wash in running tap water, slides were stained with fresh Weigert iron hematoxylin for 2 min. Following a 10-min wash in running tap water, slides were soaked in 0.05% fast green (5 min), 1.0% acetic acid (15 s), and 0.1% safranin-O (4 min), in this order. After dehydration with alcohol and being cleared with xylene, slides were kept in xylene with molecular sieves and mounted sequentially. All slides were processed following this protocol. All experiments were performed in an air-conditioned room in order to minimize the effect of excessively high or low temperature. The prepared slides were graded according to the OARSI osteoarthritis cartilage histopathology assessment system. 18 The examination was performed by two observers in a blinded manner, and the scores were averaged to minimize observer bias. Sections were also stained with collagen type II, Sox9, and DAPI using VECTASHIELD Mounting Medium (VECTASHIELD Mounting Medium with DAPI; Vector Laboratories, Burlingame, CA) according to the manufacturer's instructions. The brightness of all images was adjusted simultaneously and identically to improve comprehension. The original images are provided as a supplemental file.
Statistical Analysis
Data are presented as means AE standard deviation. Cell viability assay data were analyzed by unpaired t-test. Gene expression and ELISA data were analyzed by a paired t-test. The gross morphology and histology data were analyzed using a Steel-Dwass test. All analyses were performed using the JMP Pro software program (SAS Institute, Inc., Cary, NC). Differences were considered significant at a level of p 0.05.
RESULTS
Selection of Effective Statin and Assessment of Fluvastatin Toxicity in Primary Chondrocytes
First, we assessed the effects of typical statins on human OA primary chondrocytes. Each statin was added to the medium for a final concentration of 10 mM, and gene expression was analyzed. Results of a real-time PCR expression analysis showed that anabolic gene expression (such as that of collagen type II and aggrecan) was promoted most effectively by fluvastatin ( Fig. 2A) . Fluvastatin also showed the most potent suppressive effect on MMP13 gene expression. From these results, we determined that fluvastatin has the strongest anabolic and anti-catabolic effects on human chondrocytes. As the next step, we investigated the effect of fluvastatin on chondrocyte cell viability. Incubation with fluvastatin at three different concentrations for 24 h did not affect chondrocyte cell viability (Fig. 2B) .
Chondroprotective Effects of Fluvastatin on Primary Human Chondrocytes In Vitro Next, we investigated the effects of fluvastatin on gene expression of collagen type II, aggrecan, Sox9, and MMP13 with or without IL-1b stimulation using human OA chondrocytes (Fig. 3A) . Gene expression of collagen type II and aggrecan was significantly promoted with fluvastatin treatment at steady state and IL-1b-stimulated state, indicating an enhanced chondrogenic induction. Sox9 gene expression was also promoted, but the significant difference was only observed at steady state. On the other hand, treatment with 1 mM and 10 mM fluvastatin inhibited MMP13 gene expression in both steady state and IL-1b-stimulated state OA chondrocytes. IL-1b stimulation itself increased the MMP13 gene expression dramatically. In contrast, IL-1b stimulation decreased Sox9 gene expression slightly. However, no significant influence on anabolic gene expressions including Sox9 was observed in this stimulation period. The effect of fluvastatin on MMP13 protein production in primary chondrocytes with or without IL-1b stimulation was 
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Characterization of Fluvastatin-PLGA Microspheres
First, we assessed the actual drug loading into microspheres using high-performance liquid chromatography (HPLC). The results showed that approximately 31 mg fluvastatin was loaded into 1 mg fluvastatin-PLGA microspheres (FLU-PLGA microspheres). Second, the release profile was assessed and morphological changes were observed. The cumulative release pattern showed that about 70% of the loaded fluvastatin was released from the FLU-PLGA microspheres within 3 days. After this first phase of fluvastatin release, the remaining fluvastatin was gradually released for 2 weeks as a second phase (Fig. 4A) . Morphological changes coincided with this release profile. After 7 days, the surface of the microsphere became porous and the substance of the microsphere gradually shrank. Finally, after 42 days, the microspheres were diffusely degraded (Fig. 4B) .
Gross Morphological and Histological Evaluation of Articular Cartilage
Five weeks after injection, the morphological findings in group 2-B (FLU-PLGA contralateral saline control group) showed moderate cartilage change with irregular surface fibrillation. Similar degenerative changes were observed in both groups 1-A (PLGA-treated group) and 1-B (the PLGA contralateral saline control group). Group 2-A (FLU-PLGA-treated group) showed generally intact surfaces, albeit with spot surface fibrillation areas (Fig. 5A) . Statistically significant differences were not observed among these four groups (Fig. 5B) . Histological evaluation of articular cartilage showed the same trend as morphological evaluation. The histological findings in group 2-B (FLU-PLGA contralateral saline control group) demonstrated the progression of osteoarthritic changes, including the loss of proteoglycan in the superficial and middle zones of the cartilage layers and increasing cell clustering. Group 1-B (PLGA contralateral saline control group) and group 1-A (PLGA-treated group) showed the same degree of osteoarthritic change. Group 2-A (FLU-PLGA-treated group) showed minimum surface fibrillation and no ascertainable loss of proteoglycans (Fig. 6A) . The OARSI score was significantly lower in group 2-A than in other groups (Fig. 6B) . The biochemical changes in the composition of articular cartilage were investigated by immunohistochemistry for collagen type II and Sox9. There was a notable increase in collagen type II in the matrix of cartilage in group 2-A, while no significant changes were detected in Sox9 in any group (Fig. 7) .
DISCUSSION
This study is the first to demonstrate the effects of fluvastatin-loaded PLGA microspheres on articular cartilage in an experimentally induced OA model. The in vitro study showed the effectiveness of anticatabolic and anabolic effects of fluvastatin on human OA chondrocytes. These results offer the possibility of new therapeutic materials to prevent the progression of OA.
The early stage of OA is sometimes caused by trauma such as meniscus rupture or ACL injury. 
FLUVASTATIN-PLGA MICROSPHERES REDUCE OSTEOARTHRITIS
Although ACL rupture in younger patients is treated surgically with a satisfactory short-term outcome, ACLreconstructed knees showed a higher incidence and severity of OA than control knees. 20 Meniscectomy is often performed for meniscus tears, and subsequent cartilage degeneration often occurs, especially in older patients. 21 While these patients are sometimes treated with hyaluronic acid, there is no clear evidence that it slows disease progression. 22 For these patients, diseasemodifying drugs are desired to prevent OA progression to an advanced stage. Thus, we searched for possible candidates of disease-modifying drugs. In previous studies, statins were reported to be chondroprotective both in vitro and in vivo. 12, [23] [24] [25] At the beginning of our study, we assessed several clinically used statins with OA chondrocytes. We found that fluvastatin was most effective in increasing expression of anabolic genes and decreasing expression of the MMP13 gene, which is a key degenerative enzyme targeting the cartilage matrix. 6, 26, 27 This is partly because fluvastatin has relative lipophilicity in its pharmacologically active state. 28, 29 Therefore, we chose fluvastatin as a reagent for this study.
In the in vitro study, fluvastatin inhibited catabolic responses in OA chondrocytes, such as the production of the matrix degrading enzyme MMP-13 and the downregulation of matrix proteins in cartilage. In addition, when the cells were stressed by the OAinducing factor IL-1b, the same tendencies were observed. These in vitro results show that fluvastatin has anti-degenerative and anabolic effects in both stable state and acute state OA chondrocytes.
Then, we considered an appropriate administration route to deliver fluvastatin to chondrocytes in vivo. A previous study of a murine collagen-induced arthritis model reported that intraperitoneal administration of simvastatin suppressed the progression of acute to chronic joint inflammation in vivo. 30 However, systemic administration of a very high dose of simvastatin (i.e., 40 mg/(kgÁd)) was required for the beneficial anti-inflammatory effects. If such a high dose of statin is administered systemically, rhabdomyolysis with acute renal failure may occur as a severe side effect.
11 Such a high therapeutic dosage for the anti-inflammatory effect was likely required because of the different distribution ratios of the drug between serum and synovial fluid. 31 Intra-articular injection is therefore a suitable way to achieve an adequate concentration in synovial fluid without excess increase of serum statin concentration.
The frequency of administration should also be discussed. While hyaluronic acid has been used for treating early-stage symptomatic OA, the need for multiple weekly intra-articular injections resulted in poor patient compliance. Furthermore, intra-articular injections can cause knee joint infection. 32, 33 To solve these problems, we introduced PLGA microspheres as a DDS. These particles have numerous micro poles in which the statin is encapsulated. PLGA is broken down by hydrolytic cleavage into lactic acid and glycolic acid in biological fluids. 34 The biodegradable nature of these particles is believed to allow for gradual release of the statin. In one study, leuprolide acetate, a peptide drug for prostate cancer, showed a 1-month sustained-release profile from PLGA particles. 17 Another study reported that an intra-articular injection of PLGA microspheres with sulforaphane showed chondroprotective effects and no harmful effects in cartilage. 13 In our in vitro release experiment, fluvastatin was released biphasically in PBS. The PLGA itself was almost degraded in 35 days. Because of the rapid disappearance of the drug from intra-articular space into serum when its molecular form is injected, 35, 36 the concentration would change dramatically and multiple injections would be needed. Therefore, a suitable DDS is an important factor to consider for administering statin into synovial space more effectively. We estimated the synovial fluid concentration of fluvastatin by using terminal halflives of various drugs in synovial fluid 37 and estimated the synovial fluid volume of arthritic rabbit model. 38 At the outset, based on our in vitro release test results, we divided the release phase into acute (day 1-3) and gradual (day 4-14) phases. Next, we estimated fluvastatin terminal half-life as 8.17 h (Et 1/2 ) according to molecular weight. Then, the hours of each phase were divided by doubled Et 1/2 (simplified clearance time, SCt). Finally, the total release amount of each phase was divided by SCt and estimated synovial fluid volume (0.7205 ml). According to this procedure, the estimated fluvastatin concentrations in synovial fluid were 7.07 mg/ml and 0.76 mg/ml in the acute and gradual phases, respectively. Our in vitro study revealed that the concentration of fluvastatin from Figure 5 . In vivo macroscopic influence of fluvastatin-PLGA microspheres. OA was surgically induced by the ACL transection. Rabbits were then treated with 1 mg/kg of PLGA microspheres (group 1-A), saline to group 1-A contralateral knee (group 1-B), 1 mg/kg fluvastatin-PLGA microspheres (group 2-A), or saline to group 2-A contralateral knee (group 2-B). After 5 weeks, the rabbits were sacrificed. Femoral and tibia articular cartilage was stained with India ink. The representative macroscopic observation (A). Group 2-A showed lower scores, yet no significant difference was detected among groups in the morphological assessment (B) (n ¼ 5, NS: not significant).
FLUVASTATIN-PLGA MICROSPHERES REDUCE OSTEOARTHRITIS 1 mM (0.43 mg/ml) to 10 mg/ml (4.3 mg/ml) had dosedependent chondroprotective effects. These results mostly coincided with the estimated fluvastatin concentration in synovial fluid. In addition to the results, both the efficacy of statin and PLGA microspheres has been confirmed by various studies. 12, 13, 17, [23] [24] [25] Hence, we considered this combination as a potential candidate of a monthly administered, intra-articular injectable drug.
There are effective therapies for advanced stages of OA, such as high tibial osteotomy (HTO) or total knee arthroplasty (TKA), and these approaches show good and stable outcomes. 39, 40 These strategies can affect the disease condition dramatically. However, with regard to early stage OA, there is no decisive treatment to radically modify the disease. In our in vivo experiment, the progression of OA was limited to the relatively early stages because of the comparably short experiment time span. In these experimental conditions, the ECM concentration was maintained by using statin loaded onto PLGA. These results show that this agent has a beneficial effect on early stage OA by acting as a promoter of anabolic effects or an inhibitor of catabolic effects. There are many candidates reported to be diagnostic markers for early stage OA. 41 By using these emerging tools that enable more precise, early OA diagnosis, these statin-loaded PLGA microspheres can play a critical role in treatment strategy for OA, especially at early stages.
There are several limitations in this study, which require consideration. First, it is difficult to match precisely the appropriate concentration in vitro with the dosage in vivo. While it is desirable to monitor the concentration of fluvastatin within the joint space, it was very difficult and impractical to aspirate the joint fluid several times from the small knee-joint space of the rabbit. We measured serum fluvastatin concentrations at 1, 3, and 5 weeks after injection by using HPLC as an alternative way to assess the synovial fluid concentration, but the serum concentrations were under the threshold of detection. This was caused by the drug distribution difference between synovial fluid and serum in cases where the drug is injected into the articular space. 31 Before proceeding to the clinical trial stage, further studies with larger experimental animals like dog or pig are required to obtain the actual concentration data for synovial fluid. Second, in vitro studies were performed with chondrocytes after digestion by collagenase. Although the cells were used for the experiment within two passages, the phenotype may not completely coincide with that of chondrocytes embedded in cartilage tissue. Third, the fluvastatin 
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dosage used for in vivo experiments is an issue. The encapsulation efficiency was enormously influenced by the volume of internal water phase that contained the drug. The ratio of drug to PLGA also affects the drug release kinetics from microspheres. 42 These characteristics of microspheres manufactured by the (w/o)/w emulsion procedure made it difficult to equalize the PLGA amount when we tried to assess the effects of different fluvastatin dosages in in vivo experiments while maintaining the same characteristics of drug release kinetic. For these reasons, we used the single dosage of fluvastatin with the amount of 1 mg/kg FLU-PLGA microspheres as a fluvastatin-treated group based on the previous study. However, conditions that are more suitable may exist for inhibiting OA changes. Finally, we could not completely rule out individual differences of each animal stemming from genetic control insufficiency, which may have affected the experiment results.
Although these limitations exist and additional assessment is required, this study showed that statinloaded PLGA can prevent OA progression and promote anabolic effects. These findings demonstrated the possibility of using statin-containing PLGA microspheres as a therapeutic agent to slow the OA progression from early stage to advanced stage.
CONCLUSION
A single intra-articular injection of PLGA/fluvastatin microspheres inhibited the progression of cartilage degeneration in an experimentally induced OA model. The in vitro studies suggest that the sustained release of statin from the PLGA microspheres maintained the chondroprotective effects of statin, such as the inhibition of the expression of matrix-degrading enzymes and the increased expression of extracellular matrix genes. The intra-articular injection of gradually released statin may be promising as a disease-modifying therapy for early stage OA.
